1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Colorectal Cancer Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Modality and End User

Colorectal Cancer Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Modality and End User

  • June 2022
  • 259 pages
  • ID: 6295657
  • Format: PDF
  • The Insight Partners

Summary

Table of Contents

Search Inside

The global colorectal cancer market is expected to grow from US$ 18,619.3 million in 2022 to US$ 24,078.5 million by 2028; it is expected to grow at a CAGR of 3.3% from 2022 to 2028.

Factors such as the increasing prevalence of colorectal cancer, product launches, and benefits offered by generic drugs are driving the growth of the global colorectal cancer market. However, pricing pressure on drug manufacturers is hampering the global colorectal cancer market growth.

Colorectal cancer, also known as bowel cancer, colon cancer, or rectal cancer, is any form of cancer that affects the colon and the rectum.Colon and rectal cancer are often grouped together as many features are common in them.

The majority of colorectal cancers generally develop over time from adenomatous (precancerous) polyps.Colorectal cancer may be benign, or non-cancerous, or malignant.

Some of the risk factors for colorectal cancer involve a family history of colon or rectal cancer, diet, alcohol intake, smoking and inflammatory bowel disease.The symptoms shown by the patients who have colon cancer include changes in bowel habits, diarrhea or constipation, blood in stools that make it look black.

Colorectal cancer can be treated with chemotherapy, radiotherapy, and surgery.
The increasing medical tourism and the growing pharmaceutical industry in emerging countries are expected to boost the global colorectal cancer market growth.According to India Brand Equity Foundation (IBEF) statistics in April 2019, India is the largest provider of generic drugs worldwide.

The Indian pharmaceutical industry supplies ~40% of generic demand in the US, with ~50% of the global demand for multiple vaccines and 25% of all medicines in the UK.The pharmaceutical sector in India is expected to grow from US$ 42 billion in 2021 to US$ 55 billion by 2025; it is estimated to register at a CAGR of 37% from 2020 to 2025.

Moreover, India has a huge pool of scientists and engineers having the potential to grow the healthcare industry remarkably.
Major market players focus on emerging markets such as Singapore and China as they have many colorectal cancer patients and growing medical tourism.As per the Australian Institute of Health and Welfare, over ~15,540 new cases of colorectal cancer were diagnosed in 2021.

Moreover, as per the Malaysia Healthcare Travel Council, in 2019, over 1.22 million healthcare travelers visited Malaysia for healthcare purposes. The low cost of treatment and incorporation of advanced technologies to provide less waiting time for procedures in Asia Pacific are likely to boost the number of surgeries. This ultimately increases the demand for colorectal cancer diagnostics and treatment.

Many key market players are involved in manufacturing a wide range of drugs and diagnostic tests that help in reducing the burden of colorectal cancer.For instance, in June 2021, Bristol Myers Squibb announced the approval of Opdivo plus Yervoy by the European Commission (EC) for the treatment of adult patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer.

In July 2020, Taiho Pharmaceutical Co., Ltd. launched LONSURF, its anticancer agent, for the treatment of patients with metastatic colorectal cancer. With the launch of this product in China, the company expected that Lonsurf would offer a broader contribution to patients and medical institutions as a new treatment option for patients with colorectal cancer. Furthermore, inorganic developments by the key players of the global colorectal cancer market will also help the market to grow. For instance, Epigenomics AG announced its Next Generation Liquid Biopsy Test for colorectal cancer screening and planned to appeal the National Coverage Determination (NCD) decision in 2021. Thus, the constant developments and new product launches in colorectal cancer diagnostics and therapeutics are driving the global colorectal cancer market growth.
The global colorectal cancer market is bifurcated into modality and end user.Based on modality, the global colorectal cancer market is segmented into diagnosis type, therapy type, and imaging type.

The diagnosis type segment is estimated to account for the largest market share and is expected to register the highest CAGR during the forecast period.Colorectal cancer or CRC is the most frequent human malignant neoplasms.

The diagnostics emphasize the need for early recognition of neoplasms in the asymptomatic or precancerous stage.Therefore, early recognition is essential in patients with acute symptoms and adverse course of the disease.

The diagnosis type segment holds the largest share of the global colorectal cancer market in 2022. The diagnosis type is further segmented into immunohistochemistry, stool test, flexible sigmoidoscopy, colonoscopy, CEA test, and others. Moreover, the stool test segment is anticipated to register the highest CAGR in the market during the forecast period. Stool-based tests are noninvasive for colorectal cancer screening options. For this test, no special diet or bowel preparation is required. Stool-based tests are recommended for patients with an average risk for colorectal cancer or no personal history. Further, guaiac-based fecal occult blood test (gFOBT) and fecal immunochemical test (FIT) are the noninvasive tests practiced to find blood in the stool that may be a symptom of cancer or large polyps. These tests can be taken at home with a kit after following instructions. Another type of noninvasive test is Stool DNA testing, which looks for certain DNA or gene changes that often get into the stool, which can be a sign of cancer if a stool DNA test results in abnormal. Fecal occult blood testing (FOBT) is the most widely prescribed screening test for CRC as it is simple, noninvasive, and has been demonstrated to reduce the chances of death due to CRC. For instance, Clinical Genomics Technologies Pty Ltd offers InSure ONE (Fecal Immunochemical testing) for detecting blood in the stool, which helps to diagnose CRC.
The World Health Organization (WHO), American Cancer Society, Centers for Disease Control and Prevention (CDC), and GLOBOCAN: Global Cancer Observatory are among the primary and secondary sources referred to while preparing the report on the global colorectal cancer market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

ref:plp2022

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on